What are the most significant ways AI is accelerating drug discovery and development in biotechnology?
Most answers highlight AI's impact on accelerating drug design, data generation, and trial processes, with some emphasizing automation, improved decision-making, and value chain transformation across biotechnology.
17 answers
Answers

Michael Ehlers
Entrepreneur Partner · MPM BioImpact
Breaking Data Silos
Michael Ehlers says breaking down data silos across drug discovery and development teams is a significant way AI is accelerating the field, enabling agentic research across biotech processes.
Decoding Bio · Decoding Bio · Read
Samir Kaul
Founding General Partner · Khosla Ventures
Faster patient selection
Samir Kaul says the biggest way to compress the drug development cycle is picking better patients for trials, which lets companies enroll people quicker and raise the odds a drug works.
The answer starts at 6:27.
MTS · Listen on Apple Podcasts

Packy McCormick
Founder · Not Boring
Generating thousands of designs
Packy McCormick says AI's significant contribution is generating thousands of designs rapidly, citing Claude producing about 35,000 antibody designs in a month at Divergence Labs.
Not Boring by Packy McCormick · Not Boring by Packy McCormick · Read

Benjamine Liu
CEO and Co-founder at Formation Bio · Formation Bio
Target matching & trial acceleration
Benjamine Liu says his firm's AI tools help match the right drug target to the right indication, design studies, and run trials faster, alongside drug development capabilities.
The answer starts at 25:52.
MTS · Listen on Apple Podcasts

Kevin Weil
CEO
Automated Labs Generating Data
Kevin Weil says AI models are data-poor in the sciences, so the way to make progress is to build large-scale automated labs that generate data at volume to make AI models better in science.
The answer starts at 11:01.
MTS · Listen on Apple Podcasts
Stephen Hoge
President · Moderna
Speeding design productivity
Stephen Hoge says the case for optimism about AI in biotech starts with productivity, since AI accelerates tasks like sequence and protein design and trial enrollment that once took a whole team, and that productivity gain alone should have a huge impact on addressing health.
Blackstone · Watch on YouTube

Harry Stebbings
Founder · 20vc
Automating wet labs
Harry Stebbings says wet labs are going to become automatable, with an AI brain reasoning over large data sets in ways a single human can't, which he expects to accelerate the pace of drug discovery.
20VC with Harry Stebbings · Watch on YouTube

Joshua Weiner
Senior Vice President Consumer Engagement & Analytics · Cvs Health
Molecular generation
Joshua Weiner says his company CHAI has started on molecular generation because he sees it as the apex for the other things that can happen around it.
The answer starts at 20:48.
Stanford Online: University Courses & Lectures · Listen on Apple Podcasts

Sam Rahman
Portfolio Manager & Partner · Hedgeye Asset Management, Llc
Better efficacy & side-effect profiles
Sam Rahman says AI can be used to create molecules and biological compounds with better side-effect profiles and better efficacy, and that AI can improve and optimize drug R&D so better products reach the market faster.
New York Stock Exchange · Watch on YouTube

Nworah Ayogu
Partner · Thrive Capital
Across the entire value chain
Nworah Ayogu says AI's effect on drug discovery will change the entire value chain, extending beyond discovery to manufacturing, clinical trials and commercialization.
Sourcery with Molly O'Shea · Watch on YouTube

Alex Zhavoronkov
Chief Executive Officer and Chief Business Officer · Insilico Medicine
Generative models & automation
Zhavoronkov posted that "prompt to drug is now possible in low-moderate novelty space."
Where Tech Meets Bio · Where Tech Meets Bio · Read

Peter H. Diamandis
Founder & Curator · Abundance360
Parallel organoid testing
Peter H. Diamandis cites Parallel Bio's organoids, which he says got FDA approval to skip animal trials because testing drugs on them in parallel is more predictive of how drugs behave in real human bodies.
The answer starts at 17:20.
Moonshots with Peter Diamandis · Listen on Apple Podcasts
Mukhtar Ahmed
Chief Executive Officer · BC Platforms
Improving decision quality
Mukhtar Ahmed says the next wave of AI in biopharma should focus on helping organizations decide which options deserve resources, arguing technology creates more value when applied to an explicit decision framework.
The answer starts at 15:17.
The AI in Business Podcast · Listen on Apple Podcasts

Palmer Luckey
Founder · Anduril Industries
Digital twin cell simulations
Palmer Luckey says AI will be used to train digital twins of cells and then run exhaustive searches of intervention space to find how to move a diseased cell to a healthy state, which he says turns biology problems into search problems.
The answer starts at 14:20.
ASI pill · Listen on Apple Podcasts

Sylke Poehling, PhD
SVP and Global Head: Therapeutic Modalities, pRED; Roche Gene Therapy Center of Excellence · Roche
Designing molecular sequences
Sylke Poehling says AI's clearest value is in design, such as building and testing large libraries of AAV capsid variants in parallel so a model can learn which sequences have the needed properties, because experiments close to a sequence can be run at scale.
Life Science Connect · Watch on YouTube

Olivier Litzka
Partner · Andera Partners
Improving every step
Olivier Litzka says most biotech companies now use AI at every single development step, in one extent or another, and that AI can already significantly improve every single step.
Life Science Connect · Watch on YouTube

Fiona H. Marshall
President, Biomedical Research · Novartis
New target discovery
Fiona H. Marshall says one area she is most excited about is using AI to discover new biology and new targets, citing a new department called Target Identification that uses AI to discover new targets.
Vanguards of Healthcare by Bloomberg Intelligence · Vanguards of Healthcare by Bloomberg Intelligence · Listen at 45:50
